CRO概念股震荡拉升 药石科技涨超10%

Core Viewpoint - The CRO (Contract Research Organization) sector experienced a significant rally, with notable stock price increases for several companies, particularly药石科技, which rose over 10% [1] Group 1: Company Performance - 药明康德 reported a net profit of 8.561 billion yuan for the first half of the year, marking a year-on-year increase of 101.92% [1] - 药明康德 plans to distribute a cash dividend of 3.5 yuan per 10 shares (including tax) [1] - The company has revised its revenue forecast for 2025, increasing the expected range from 41.5-43 billion yuan to 42.5-43.5 billion yuan [1] Group 2: Market Reaction - Other companies in the CRO sector, including 九洲药业, 海特生物, 翰宇药业, and 益诺思, saw stock price increases of over 5% [1] - The overall positive sentiment in the market is reflected in the performance of multiple CRO stocks, indicating a bullish trend in the sector [1]